Protalix BioTherapeutics
PLX
63 hedge funds and large institutions have $11.9M invested in Protalix BioTherapeutics in 2024 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 16 increasing their positions, 21 reducing their positions, and 11 closing their positions.
265% more call options, than puts
Call options by funds: $62K | Put options by funds: $17K
1.01% less ownership
Funds ownership: 13.86% → 12.85% (-1%)
5% less funds holding
Funds holding: 66 → 63 (-3)
24% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 21
27% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 11
34% less capital invested
Capital invested by funds: $18M → $11.9M (-$6.08M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$238K |
| 2 |
VF
Virtu Financial
New York
|
+$235K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$61K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$56.4K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$44.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$487K |
| 2 |
BlackRock
New York
|
-$220K |
| 3 |
DA
Denali Advisors
San Diego,
California
|
-$169K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$132K |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$126K |
PLX Hedge Fund Activity: Q1 2024 in Review
63 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q1 2024, worth a combined $11.9M — down 34% from $18M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of PLX and 8 opened new positions — a net loss of 3 holders — while 21 trimmed existing stakes and 16 added.
The largest buyer was Renaissance Technologies, adding an estimated $238K. The largest seller was Morgan Stanley, cutting an estimated $487K.
- 63 institutional investors held Protalix BioTherapeutics (PLX) as of Q1 2024, down from 66 in Q4 2023.
- Funds reported $11.9M of Protalix BioTherapeutics stock for Q1 2024, down 34% quarter-over-quarter.
- 8 funds opened new Protalix BioTherapeutics positions in Q1 2024 and 11 closed out, a net change of -3 holders.
- The largest Protalix BioTherapeutics buyer in Q1 2024 was Renaissance Technologies, an estimated $238K added.
- The largest Protalix BioTherapeutics seller in Q1 2024 was Morgan Stanley, an estimated $487K sold.
Based on aggregated 13F filings for Q1 2024.